Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing-Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
04 07 2023
04 07 2023
Historique:
received:
16
08
2022
accepted:
02
03
2023
pmc-release:
04
07
2024
medline:
5
7
2023
pubmed:
19
4
2023
entrez:
18
4
2023
Statut:
ppublish
Résumé
Cognitive impairment is a common and impactful symptom of relapsing-remitting multiple sclerosis (RRMS). Cognitive outcome measures are often used in cross-sectional studies, but their performance as longitudinal outcome measures in clinical trials is not widely researched. In this study, we used data from a large clinical trial to describe change on the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) over up to 144 weeks of follow-up. We used the data set from DECIDE (clinicaltrials.gov identifier NCT01064401), a large randomized controlled RRMS trial to describe change on the SDMT and PASAT over 144 weeks of follow-up. We compared change on these cognitive outcomes with change on the timed 25-foot walk (T25FW), a well-established physical outcome measure. We investigated several definitions for clinically meaningful change: any change, 4-point change, 8-point change, and 20% change for the SDMT, any change, 4-point change, and 20% change for the PASAT, and 20% change for the T25FW. DECIDE included 1,814 trial participants. SDMT and PASAT scores steadily improved throughout follow-up: the SDMT from a mean 48.2 (SD, 16.1) points at baseline to 52.6 (SD 15.2) at 144 weeks and the PASAT from 47.0 (SD 11.3) at baseline to 50.0 (SD 10.8) at 144 weeks. This improvement in scores is most likely due to a practice effect. Throughout the trial, participants were more likely to experience improvement than worsening of their SDMT and PASAT performance, whereas the number of worsening events on the T25FW steadily increased. Changing the definition of clinically meaningful change for the SDMT and PASAT or using a 6-month confirmation changed the overall number of worsening or improvement events but did not affect the overall behavior of these measures. Our findings suggest that the SDMT and PASAT scores do not accurately reflect the steady cognitive decline that people with RRMS experience. Both outcomes show postbaseline increases in scores, which complicates the interpretation of these outcome measures in clinical trials. More research into the size of these changes is needed before recommending a general threshold for clinically meaningful longitudinal change.
Sections du résumé
BACKGROUND AND OBJECTIVES
Cognitive impairment is a common and impactful symptom of relapsing-remitting multiple sclerosis (RRMS). Cognitive outcome measures are often used in cross-sectional studies, but their performance as longitudinal outcome measures in clinical trials is not widely researched. In this study, we used data from a large clinical trial to describe change on the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) over up to 144 weeks of follow-up.
METHODS
We used the data set from DECIDE (clinicaltrials.gov identifier NCT01064401), a large randomized controlled RRMS trial to describe change on the SDMT and PASAT over 144 weeks of follow-up. We compared change on these cognitive outcomes with change on the timed 25-foot walk (T25FW), a well-established physical outcome measure. We investigated several definitions for clinically meaningful change: any change, 4-point change, 8-point change, and 20% change for the SDMT, any change, 4-point change, and 20% change for the PASAT, and 20% change for the T25FW.
RESULTS
DECIDE included 1,814 trial participants. SDMT and PASAT scores steadily improved throughout follow-up: the SDMT from a mean 48.2 (SD, 16.1) points at baseline to 52.6 (SD 15.2) at 144 weeks and the PASAT from 47.0 (SD 11.3) at baseline to 50.0 (SD 10.8) at 144 weeks. This improvement in scores is most likely due to a practice effect. Throughout the trial, participants were more likely to experience improvement than worsening of their SDMT and PASAT performance, whereas the number of worsening events on the T25FW steadily increased. Changing the definition of clinically meaningful change for the SDMT and PASAT or using a 6-month confirmation changed the overall number of worsening or improvement events but did not affect the overall behavior of these measures.
DISCUSSION
Our findings suggest that the SDMT and PASAT scores do not accurately reflect the steady cognitive decline that people with RRMS experience. Both outcomes show postbaseline increases in scores, which complicates the interpretation of these outcome measures in clinical trials. More research into the size of these changes is needed before recommending a general threshold for clinically meaningful longitudinal change.
Identifiants
pubmed: 37072219
pii: WNL.0000000000207301
doi: 10.1212/WNL.0000000000207301
pmc: PMC10351309
doi:
Banques de données
ClinicalTrials.gov
['NCT01064401']
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1-e11Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 American Academy of Neurology.
Références
N Engl J Med. 2015 Oct 8;373(15):1418-28
pubmed: 26444729
Mult Scler. 2022 Jun;28(7):1101-1111
pubmed: 34612114
PLoS One. 2020 Feb 21;15(2):e0228064
pubmed: 32084191
Arch Clin Neuropsychol. 2015 Aug;30(5):424-34
pubmed: 25994156
Mult Scler. 2007 Sep;13(8):1004-10
pubmed: 17623735
Mult Scler. 2018 Nov;24(13):1665-1680
pubmed: 30303036
Mult Scler. 2017 Apr;23(5):721-733
pubmed: 28206827
Neurology. 2002 Apr 23;58(8):1294-6
pubmed: 11971105
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Mult Scler. 2017 Apr;23(5):704-710
pubmed: 28206828
Neurology. 2021 Jan 19;96(3):e376-e386
pubmed: 33328324
Mult Scler. 2019 Nov;25(13):1781-1790
pubmed: 30334474
J Med Internet Res. 2021 Nov 18;23(11):e30394
pubmed: 34792480
Eur J Neurol. 2021 Jun;28(6):2115-2120
pubmed: 33448539
Neurology. 1991 May;41(5):685-91
pubmed: 2027484
Arch Clin Neuropsychol. 2006 Jan;21(1):53-76
pubmed: 16290063
Neurology. 2021 Oct 19;97(16):e1560-e1570
pubmed: 34433679
Arch Clin Neuropsychol. 2011 Jun;26(4):356-63
pubmed: 21555787
Clin Neuropsychol. 2010 Oct;24(7):1131-45
pubmed: 20830649
Mult Scler. 2018 May;24(6):795-804
pubmed: 28485186
Arch Clin Neuropsychol. 2007 Jan;22(1):15-24
pubmed: 17142007
Arch Clin Neuropsychol. 1999 Apr;14(3):273-84
pubmed: 14590596
Alzheimers Dement. 2014 Nov;10(6):675-83
pubmed: 24656850
Neurology. 2016 Sep 06;87(10):978-87
pubmed: 27511182